Fibromyalgia-pathways and neurotransmitters

Human Psychopharmacology

Volumn 24, Issue SUPPL. 1, 2009, Pages

  Stahl, Stephen M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEUROSCIENCE EDUCATION INSTITUTE   (United States)

Author keywords

fibromyalgia; neurobiology; neurotransmitters; noradrenaline; serotonin; substance P

Indexed keywords

CALCIUM CHANNEL; DOPAMINE; NEUROTRANSMITTER; NEUROTRANSMITTER TRANSPORTER; NORADRENALIN; SEROTONIN; SUBSTANCE P; VOLTAGE DEPENDENT ANION CHANNEL; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

AFFECT; ARTICLE; CHRONIC PAIN; COGNITION; COGNITIVE DEFECT; FATIGUE; FIBROMYALGIA; HUMAN; NEUROTRANSMITTER RELEASE; NOCICEPTION; NORADRENERGIC SYSTEM; PAIN; PRIORITY JOURNAL; SENSORY NERVE; SEROTONINERGIC NERVE CELL; SLEEP DISORDER; SPINAL CORD DORSAL HORN; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECT; METABOLISM; PAIN THRESHOLD; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; COGNITION DISORDERS; FIBROMYALGIA; HUMANS; MODELS, NEUROLOGICAL; NEUROTRANSMITTER AGENTS; PAIN; PAIN THRESHOLD; SIGNAL TRANSDUCTION; SLEEP DISORDERS;

EID: 68849093756     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1029     Document Type: Article

References (53)

1. Andersen ML, Nascimento DC, Machado RB, Roizenblatt S, Moldofsky H, Tufik S,. 2006. Sleep disturbance induced by substance P in mice. Behav Brain Res 167: 212-218.
2. Apkarian AV, Sosa Y, Sonty S, et al,. 2004. Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J Neurosci 24: 10410-10415.
3. Arnold LM, Hudson JI, Keck PE Jr, Auchenbach MB, Javaras KN, Hess EV,. 2006. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry 67: 1219-1225.
4. Baliki MN, Geha PY, Apkarian AV, Chialvo DR,. 2008. Beyond feeling: chronic pain hurts the brain, disrupting the default-mode network dynamics. J Neurosci 28: 1398-1403.
5. Bennett RM,. 1999. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc 74: 385-398.
6. Bennett R,. 2005. Fibromyalgia: present to future. Curr Rheumatol Rep 7: 371-376.
7. Bonnot O, Tordjman S,. 2008. Schizophrenia and pain reactivity [article in French]. Presse Med 37: 1561-1568.
8. Briley M,. 2003. New hope in the treatment of painful symptoms in depression. Curr Opin Investig Drugs 4: 42-45.
9. Briley M, Moret C,. 2008. Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr 13 (Suppl. 11): 22-26.
10. Clauw DJ,. 2008. Pharmacotherapy for patients with fibromyalgia. J Clin Psychiatry 69 (Suppl. 2): 25-29.
11. Clauw DJ, Crofford LJ,. 2003. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol 17: 685-701.
12. Coderre TJ, Kumar N, Lefebvre CD, Yu JSC,. 2005. Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem 94: 1131-1139.
13. Defrin R, Ginzburg K, Solomon Z, et al,. 2008. Quantitative testing of pain perception in subjects with PTSD-implications for the mechanism of the coexistence between PTSD and chronic pain. Pain 138: 450-459.
14. Devoto P, Flore G, Pani L, Gessa GL,. 2001. Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. Mol Psychiatry 6: 657-664.
15. Devoto P, Flore G, Saba P, Fà M, Gessa GL,. 2005. Stimulation of the locus coeruleus elicits noradrenaline and dopamine release in the medial prefrontal and parietal cortex. J Neurochem 92: 368-374. (Pubitemid 40194027)
16. Dickenson AH,. 1990. A cure for wind up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol Sci 11: 307-309.
17. Eide PK,. 2000. Wind-up and the NMDA receptor complex from a clinical perspective. Eur J Pain 4: 5-15.
18. Fehrenbacher JC, Taylor CP, Vasko MR,. 2003. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 105: 133-141.
19. Fields HL, Heinricher MM, Mason P,. 1991. Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci 14: 145-219.
20. Glass JM,. 2008. Fibromyalgia and cognition. J Clin Psychiatry 69 (Suppl. 2): 20-24.
21. Gracely RH, Petzke F, Wolf JM, Clauw DJ,. 2002. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 46: 1333-1343.
22. Herrero JF, Laird JM, Lopez-Garcia JA,. 2000. Wind-up of spinal cord neurones and pain sensation: much ado about something? Prog Neurobiol 61: 169-203.
23. Hoffman DL, Dukes EM,. 2008. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract 62: 115-126.
24. Holman AJ, Myers RR,. 2005. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 52: 2495-2505.
25. Huynh CN, Yanni LM, Morgan LA,. 2008. Fibromyalgia: diagnosis and management for the primary healthcare provider. J Womens Health (Larchmt) 17: 1379-1387.
26. Kranzler JD, Gendreau JF, Rao SG,. 2002. The psychopharmacology of fibromyalgia: a drug development perspective. Psychopharmacol Bull 36: 165-213.
27. Kuchinad A, Schweinhardt P, Seminowicz DA, Wood PB, Chizh BA, Bushnell MC,. 2007. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain? J Neurosci 27: 4004-4007.
28. Lépine JP, Briley M,. 2004. The epidemiology of pain in depression. Hum Psychopharmacol 19 (Suppl. 1): S3-S7.
29. McMahon SB, Koltzenburg M,. (eds) 2005. Wall and Melzack's Textbook of Pain (5th edn). Churchill Livingstone: Oxford.
30. Mease PJ,. 2005. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol 75: 6-21.
31. Moldofsky H,. 1982. Rheumatic pain modulation syndrome: the interrelationships between sleep, central nervous system serotonin, and pain. Adv Neurol 33: 51-57.
32. Moldofsky H,. 2008. The significance, assessment, and management of non-restorative sleep in fibromyalgia syndrome. CNS Spectr 13 (Suppl. 5): 22-26.
33. Neumann L, Buskila D,. 2003. Epidemiology of fibromyalgia. Curr Pain Headache Rep 7: 362-368.
34. Previc FH,. 1999. Dopamine and the origins of human intelligence. Brain Cogn 41: 299-350.
35. Rashid MH, Ueda H,. 2002. Neuropathy-specific analgesic action of intrathecal nicotinic agonists and its spinal GABA-mediated mechanism. Brain Res 953: 53-62.
36. Schmahl C, Meinzer M, Zeuch A, et al,. 2008. Pain sensitivity is reduced in borderline personality disorder, but not in posttraumatic stress disorder and bulimia nervosa. World J Biol Psychiatry 29: 1-8.
37. Schwarz MJ, Späth M, Müller-Bardorff H, Pongratz DE, Bondy B, Ackenheil M,. 1999. Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients. Neurosci Lett 259: 196-198.
38. Sierralta F, Pinardi G, Miranda HF,. 1995. Effect of p- chlorophenylalanine and alpha-methyltyrosine on the antinociceptive effect of antidepressant drugs. Pharmacol Toxicol 77: 276-280.
39. Spaeth M, Briley M,. 2009 Fibromyalgia: a complex syndrome requiring a multidisciplinary approach. Hum Psychopharmacol 24 (Suppl. 1): S3-S10.
40. Stahl SM,. 2002. Does depression hurt? J Clin Psychiatry 63: 273-274.
41. Stahl SM, Grady MM, Moret C, Briley M,. 2005. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 10: 732-747.
42. Stahl SM,. 2008. Stahl's Essential Psychopharmacology (3rd edn). Cambridge University Press: Cambridge.
43. Staud R, Rodriguez ME,. 2006. Mechanisms of disease: pain in fibromyalgia syndrome. Nat Clin Pract 2: 90-98. (Pubitemid 43239208)
44. Taylor CP, Angelotti T, Fauman E,. 2007. Pharmacology and mechanism of action of pregabalin: the calcium channel α2-δ (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 73: 137-150.
45. Wall PD, Melzack R,. 2005. Textbook of Pain (5th edn). Churchill Livingstone: New York. (Section 1).
46. White KP, Harth M,. 2001. Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep 5: 320-329.
47. White LA, Birnbaum HG, Kaltenboeck A, Tang J, Mallett D, Robinson RL,. 2008. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 50: 13-24.
48. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L,. 1995. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38: 19-28.
49. Wolfe F, Smythe HA, Yunus MB, et al,. 1990. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum 33: 160-172.
50. Wood PB,. 2004. Fibromyalgia syndrome: a central role for the hippocampus: a theoretical construct. J Musculoskelet Pain 12: 19-26.
51. Woolf CJ,. 2004. Moving from symptom control toward mechanism- specific pharmacologic management. Ann Intern Med 140: 441-451.
52. Yunus MB, Ahles TA, Aldag JC, Masi AT,. 1991. Relationship of clinical features with psychological status in primary fibromyalgia. Arthritis Rheum 34: 15-21.
53. Yunus MB,. 2003. Use of a dopamine agonist in fibromyalgia: where is the evidence? J Clin Rheumatol 9: 211-214.